GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sangui Biotech International Inc (OTCPK:SGBI) » Definitions » Gross Profit

Sangui Biotech International (Sangui Biotech International) Gross Profit

: $0.08 Mil (TTM As of Mar. 2023)
View and export this data going back to . Start your Free Trial

Sangui Biotech International's gross profit for the three months ended in Mar. 2023 was $0.02 Mil. Sangui Biotech International's gross profit for the trailing twelve months (TTM) ended in Mar. 2023 was $0.08 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Sangui Biotech International's gross profit for the three months ended in Mar. 2023 was $0.02 Mil. Sangui Biotech International's Revenue for the three months ended in Mar. 2023 was $0.02 Mil. Therefore, Sangui Biotech International's Gross Margin % for the quarter that ended in Mar. 2023 was N/A%.

Sangui Biotech International had a gross margin of N/A% for the quarter that ended in Mar. 2023 => No sustainable competitive advantage


Sangui Biotech International Gross Profit Historical Data

The historical data trend for Sangui Biotech International's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangui Biotech International Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Gross Profit
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.09 0.03 0.07 0.07

Sangui Biotech International Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Gross Profit Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.01 0.04 0.01 0.02

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sangui Biotech International's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sangui Biotech International Gross Profit Distribution

For the Drug Manufacturers industry and Healthcare sector, Sangui Biotech International's Gross Profit distribution charts can be found below:

* The bar in red indicates where Sangui Biotech International's Gross Profit falls into.



Sangui Biotech International Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Sangui Biotech International's Gross Profit for the fiscal year that ended in Jun. 2022 is calculated as

Gross Profit (A: Jun. 2022 )=Revenue - Cost of Goods Sold
=0.069 - 0
=0.07

Sangui Biotech International's Gross Profit for the quarter that ended in Mar. 2023 is calculated as

Gross Profit (Q: Mar. 2023 )=Revenue - Cost of Goods Sold
=0.019 - 0
=0.02

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.08 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Sangui Biotech International's Gross Margin % for the quarter that ended in Mar. 2023 is calculated as

Gross Margin % (Q: Mar. 2023 )=Gross Profit (Q: Mar. 2023 ) / Revenue (Q: Mar. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.02 / 0.019
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Sangui Biotech International  (OTCPK:SGBI) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Sangui Biotech International had a gross margin of N/A% for the quarter that ended in Mar. 2023 => No sustainable competitive advantage


Sangui Biotech International Gross Profit Related Terms

Thank you for viewing the detailed overview of Sangui Biotech International's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Sangui Biotech International (Sangui Biotech International) Business Description

Traded in Other Exchanges
Address
Bleichenbrucke 9, Hamburg, DEU, 20354
Sangui Biotech International Inc develops pharmaceutical, medical and cosmetic products, through its subsidiary. The company develops oxygen carriers for providing oxygen transport in humans due to acute or chronic lack of oxygen and in the case of chronic wounds. It has also developed external applications of oxygen transporters in the form of sprays for healing chronic wounds and gels and emulsions for the regeneration of the skin. The products offered are artificial oxygen carriers; Chitoskin wound pads; and haemoglobin-based wound spray technology sold under the brand name Granulox. It derives revenue from licensing fees on sales of its wound spray product.
Executives
Hubertus Schmelz director NEUER WALL 54, HAMBURG 2M D-20354
Joachim Fleing director ALFRED HERRHAUSENSTR 44, WITTEN 2M 58455
Thomas Striepe director NEUER WALL 54, HAMBURG 2M D-20354
Wolfgang Barnikol director ALFRED HERRHAUSEN STR 44, WITTEN 2M 58455
Lutz Joachim director ALFRED-HERRHAUSEN-ST. 44, WITTEN 2M 58455
Christoph Ludz director SANDERSKOPPEL 17, HAMBURG 2M 22391

Sangui Biotech International (Sangui Biotech International) Headlines

No Headlines